University of Groningen

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer

PanCareLIFE Consortium; Mulder, Renée L.; Font-Gonzalez, Anna; van Dulmen-den Broeder, Eline; Quinn, Gwendolyn P.; Ginsberg, Jill P.; Loeffen, Erik A.H.; Hudson, Melissa M.; Burns, Karen C.; van Santen, Hanneke M.

Published in:
The Lancet Oncology

DOI:
[10.1016/S1470-2045\(20\)30595-7](https://doi.org/10.1016/S1470-2045(20)30595-7)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2021

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

PanCareLIFE Consortium, Mulder, R. L., Font-Gonzalez, A., van Dulmen-den Broeder, E., Quinn, G. P., Ginsberg, J. P., Loeffen, E. A. H., Hudson, M. M., Burns, K. C., van Santen, H. M., Berger, C., Diesch, T., Dirksen, U., Giwerzman, A., Gracia, C., Hunter, S. E., Kelvin, J. F., Klosky, J. L., Laven, J. S. E., ... Inthorn, J. (2021). Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *The Lancet Oncology*, 22(2), e68-e80. [https://doi.org/10.1016/S1470-2045\(20\)30595-7](https://doi.org/10.1016/S1470-2045(20)30595-7)

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer 3

Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group

Renée L Mulder*, Anna Font-Gonzalez*, Eline van Dulmen-den Broeder, Gwendolyn P Quinn, Jill P Ginsberg, Erik A H Loeffen, Melissa M Hudson, Karen C Burns, Hanneke M van Santen, Claire Berger, Tamara Diesch, Uta Dirksen, Aleksander Giwercman, Clarisa Gracia, Sarah E Hunter, Joanne F Kelvin, James L Klosky, Joop S E Laven, Barbara A Lockart, Sebastian J C M M Neggers, Michelle Peate, Bob Phillips, Damon R Reed, Eva Maria E Tinner, Julianne Byrne, Margreet Veening, Marleen van de Berg, Chris M Verhaak, Antoinette Anazodo, Kenny Rodriguez-Wallberg, Marry M van den Heuvel-Eibrink, Ogechukwu A Asogwa, Alexandra Brownsdon, W Hamish Wallace, Daniel M Green, Roderick Skinner, Riccardo Haupt, Lisa B Kenney, Jennifer Levine, Marianne D van de Wetering, Wim J E Tissing, Norbert W Paul, Leontien C M Kremer†, Julia Inthorn†, on behalf of the PanCareLIFE Consortium‡

Patients with childhood, adolescent, and young adult cancer who will be treated with gonadotoxic therapies are at increased risk for infertility. Many patients and their families desire biological children but effective communication about treatment-related infertility risk and procedures for fertility preservation does not always happen. The PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group reviewed the literature and developed a clinical practice guideline that provides recommendations for ongoing communication methods for fertility preservation for patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger and their families. Moreover, the guideline panel formulated considerations of the ethical implications that are associated with these procedures. Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the evidence and recommendations. In this clinical practice guideline, existing evidence and international expertise are combined to develop transparent recommendations that are easy to use to facilitate ongoing communication between health-care providers and patients with childhood, adolescent, and young adult cancer who might be at high risk for fertility impairment and their families.

Introduction

Damage to the reproductive organs as a result of cancer treatment in patients with childhood, adolescent, and young adult (CAYA) cancer (ie, diagnosed aged ≤ 25 years) can affect future fertility. With current 5-year survival rates exceeding 80% in the USA and Europe for patients with CAYA cancer,^{1,2} many patients who are treated with gonadotoxic therapy could have subfertility and hypogonadism.^{3,4}

Provision of information and ongoing communication about infertility risk and existing procedures for fertility preservation is essential to support patients and their families in making informed decisions about fertility preservation.⁵ Although health-care professionals have increasingly recognised the importance of fertility preservation and have introduced counselling about fertility preservation as part of patient management,⁶⁻⁸ communication about treatment-related infertility risk and methods for fertility preservation are suboptimal for many patients and their families.⁹ With fertility

preservation being a primary concern for survivors of cancer,¹⁰⁻¹³ barriers to communicating the options for fertility preservation are of importance.

Evidence-based and uniform guidance for the provision of information and ongoing communication is needed about treatment-related infertility risk and fertility preservation between health-care providers and patients and their families. Furthermore, fertility preservation raises important ethical issues (eg, counselling with minors, counselling about experimental procedures, and posthumous use of stored gametes) that are not always covered in detail in existing clinical practice guidelines (CPGs).¹⁴ Existing CPGs are not always produced by use of high-quality methodologies and do not uniformly address communication and ethical issues that are associated with fertility preservation.¹⁴ The EU-funded project, PanCareLIFE, recognised the need for global consensus on fertility preservation and established an international effort to develop transparent CPGs for fertility preservation in patients with CAYA cancer in collaboration with the

Lancet Oncol 2021; 21: e68–80

This is the third in a *Series* of three papers about fertility preservation in childhood, adolescent, and young adult cancer

*Joint first authors

†Joint last authors

‡Members are listed in the appendix pp 1–2

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands (R L Mulder PhD, A Font-Gonzalez PhD, E van Dulmen-den Broeder PhD, H M van Santen PhD, S J C M M Neggers PhD, M Veening PhD, Prof M M van den Heuvel-Eibrink PhD, O A Asogwa MSc, M D van de Wetering PhD, Prof L C M Kremer PhD, Prof W J E Tissing PhD); **Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands** (A Font-Gonzalez, Prof L C M Kremer); **Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands** (E van Dulmen-den Broeder, M Veening, M van de Berg PhD); **Department of Obstetrics and Gynecology, Department of Population Health, and Division of Medical Ethics, New York University School of**

Medicine, New York University, New York, NY, USA (Prof G P Quinn PhD); Department of Pediatric Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania (Prof J P Ginsberg MD) and Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology (C Gracia MD), University of Pennsylvania, Philadelphia, PA, USA; Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, UMC Groningen, University of Groningen, Groningen, Netherlands (E A H Loeffen PhD, Prof W J E Tissing); Department of Epidemiology and Cancer Control and Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA (M M Hudson MD, D M Green MD); Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA (K C Burns MD); Department of Pediatrics, University of Cincinnati College of Medicine, University of Cincinnati, Cincinnati, OH, USA (K C Burns); Department of Pediatric Endocrinology, Wilhelmina Children's Hospital, UMC Utrecht, Utrecht, Netherlands (H M van Santen); Department of Pediatric Hematology and Oncology Unit, University Hospital of Saint-Étienne, Saint-Étienne, France (C Berger MD); Host Research Team EA4607 Autonomic Nervous System, Epidemiology, Physiology, Exercise, and Health, Jean Monnet University of Saint-Étienne, Education and Research Cluster Lyon, Saint-Étienne, France (C Berger); Department of Pediatric Oncology and Hematology, University Children's Hospital Basel, Basel, Switzerland (T Diesch MD); Department of Pediatrics III, West German Cancer Centre, Essen University Hospital, Essen, Germany (Prof U Dirksen PhD); German Cancer Consortium (DKTK) Partner Site, Essen, Germany (Prof U Dirksen); Division of Molecular Reproductive Medicine, Department of Translational Medicine, Lund University,

International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG).^{15,16}

We provide a systematic review and recommendations for ongoing communication about treatment-related infertility risk and fertility preservation in patients with CAYA cancer, including guidance on the ethical implications that are associated with these procedures.

Data collection

Guideline panel formation

A multidisciplinary panel of 38 international specialists in paediatric oncology and haematology, radiation oncology, endocrinology (including paediatric endocrinology), reproductive medicine, gynaecology, nursing, psychology, psycho-oncology, oncofertility, ethics, epidemiology, and guideline methodology was convened (appendix pp 1–2). Members of the panel were selected (by MMH, LBK, MDvdW, LCMK, JL, and WJET) because of their experience, publications, and knowledge in the fields of paediatric and reproductive medicine, psychology, and ethics. An overview of the process and structure of guideline development is presented in the appendix (appendix pp 4–5).

Scope and definitions

The aim of this CPG is to help health-care providers to communicate the potential risk for infertility and options for fertility preservation on an ongoing basis to patients who are diagnosed with childhood cancer tumour types aged 25 years or younger and to their parents, caregivers, or partners (hereafter referred to as families), while taking into account the ethical implications that are associated with these procedures.

Systematic literature review

The experts formulated clinical questions covering the following key issues: what are the facilitators of and barriers to communication of treatment-related infertility risk and options for fertility preservation, and what are the ethical considerations related to fertility preservation (appendix p 6). Formulation of clinical questions was based on discordant areas in recommendations that were identified in existing CPGs for fertility preservation in patients with CAYA cancer, as described by Font-Gonzalez and colleagues,¹⁴ and on controversial issues that were identified within the guideline panel from discussions between panel members. Full details on the search strategies and inclusion criteria that were used to answer each clinical question are provided in the (appendix pp 7–10).

Search strategy and selection criteria

We did systematic literature searches in collaboration with Cochrane Childhood Cancer. We searched MEDLINE (through PubMed) for literature that was published between Jan 1, 1993, and Feb 21, 2020, using combinations of the search terms “childhood cancer”,

“fertility preservation”, “attitudes”, “beliefs”, “decision making”, “communication”, “barriers”, “decision tools”, and “education”. Additionally, for ethical considerations in fertility preservation, we searched Web of Science, Ethics in Medicine (through Livivo), and Bioethics Literature Database for literature that was published between Jan 1, 1993, and Feb 21, 2020, using combinations of the search terms “childhood cancer”, “fertility preservation”, “oocyte donation”, “surrogacy”, “ethics”, and “legal”. We consulted experts to establish whether additional evidence was missing, and we crosschecked references of relevant literature reviews and reports that were identified in our searches. Only reports published in English were reviewed. Eligible study populations were patients with cancer in which 75% or more of patients had been diagnosed with cancer at age 25 years or younger. All study designs were included. Eligible study outcomes were outcomes on involvement in decision making, satisfaction with and desire for information and decision aids, information needs, other facilitators for and barriers to communication, and any outcome covering ethical issues in fertility preservation.

Two primary reviewers independently selected the studies (AF-G and JI), which were crosschecked by 24 expert panel members. Detailed information from each eligible study was extracted into evidence tables and summary of findings tables. The quality of the evidence of non-qualitative studies was appraised by use of the Grading of Recommendations Assessment, Development and Evaluation¹⁷ (GRADE) approach and the evidence of qualitative studies was appraised by use of an adapted GRADE and Confidence in the Evidence from Reviews of Qualitative Research methodology.¹⁸ For the ethics working group, we used the evidence tables to extract overarching themes and subthemes of ethical arguments, principles, and issues. The evidence was carefully reviewed by the ethics experts in the working group (NWP and JI). Due to the nature of the studies covering ethical themes around fertility preservation (ie, indirect literature that is reported in descriptive studies or narrative or theoretical papers), we did not formally appraise the quality of empirical evidence but the quality of ethical reasoning was appraised by the ethics experts in the working group (NWP and JI).^{19,20}

Recommendations

Regarding the communication of infertility risk and options for fertility preservation, final recommendations were based on scientific knowledge combined with other considerations, including clinical judgment, costs, and the need to maintain flexibility across health-care systems. We followed the criteria for the strength of recommendations according to published evidence-based methods (appendix p 11).^{21,22}

The recommendations regarding ethical considerations were formulated as Good Practice Statements (GPSs) according to GRADE criteria²³ and were the result of the

evidence and arguments that were identified combined with the ethical considerations in fertility preservation that were indicated by the working group. Consensus was reached among all members of the guideline panel that the recommendations had unequivocal benefits. The recommendations were critically appraised by five independent external experts in the field (Teresa Woodruff, Anja Borgmann-Staudt, Zoltan Antal, Adam Glaser, and Rosalind McDougall; appendix p 2) and four patient or survivor representatives (AB, Jaap den Hartogh, Eline van der Meulen, and Joyce Reinecke; appendix p 3).

Findings

Of 935 articles identified, 299 were subjected to full-text review and 147 were included (figure). The conclusions of evidence are shown in panel 1 and the recommendations are presented in panels 2 and 3. We present the evidence and recommendations for the two key issues described.

What are facilitators of and barriers to the communication of treatment-related infertility risk and options for fertility preservation?

Evidence

Evidence concerning facilitators to communication of infertility risk and options for fertility preservation showed varying levels of quality. Very low-quality evidence from one study showed that some parents of male patients diagnosed with cancer before 18 years wanted to control whether physicians should discuss sperm banking with their child.²⁴ Regarding the involvement of health-care providers, one study reported that some male childhood patients with cancer considered medical support by doctors to be an important consideration, whereas only a few patients considered nursing support to be important (very low-quality evidence).²⁵ In another study, most doctors felt confident in providing up-to-date information about fertility preservation and taking a lead role in providing this information to patients and to parents, whereas most nursing staff did not feel confident in providing up-to-date information and would only take a helping role in the discussion (very low-quality evidence).²⁶

Regarding decision making, one study found that most male adolescents and young adults reported that the decision for sperm banking is a personal one and many patients reported being influenced by their parents (very low-quality evidence).²⁷ We did not find any studies that investigated the views of female patients on decision making about procedures for fertility preservation.

Decision tools and educational materials can help to facilitate communication. However, health-care providers reported that existing educational materials about fertility preservation are sometimes scarce and that the existing materials need to be improved and adapted to the patient population with CAYA cancer (moderate-quality evidence).^{28–34} New studies have evaluated the effects of brochures for fertility preservation;^{37,38} a decision aid for

Figure: Flow diagram for selection of studies

patients and families;³⁵ toolkits for health-care providers, including educational materials, checklist, referral forms, and handouts for patients;^{26,39} and clinical decision support systems to assist clinical discussions and decision making.^{36,40} These studies suggest that tools to support communication about infertility and fertility preservation have potential benefits to oncofertility care related to knowledge, empowerment, confidence levels, adherence to standards of care, and the making of informed decisions about fertility by patients and families (very low-quality evidence).^{26,35–40} On the basis of the available data, it is unclear which intervention is most effective in communicating infertility risk and options for fertility preservation.

Evidence concerning barriers to communication of infertility risk and fertility preservation showed varying levels of evidence. In regard to patient and family perspectives, there is moderate-quality evidence that poor physical status and a highly stressed emotional status of patients;^{25,41–47} time constraints regarding delaying treatment;^{25,45–48,55} costs;^{43,45,53} absence of interest;^{44,45,48} experimental nature of the procedure for fertility preservation with the associated risks;^{25,42,45,46,48,53,54} highly stressed emotional status of parents;^{44,54,56} absence of parental or medical recommendation;^{49,50} absence of patient self-efficacy for banking;^{50,51} absence of experience with, taboo regarding, and embarrassing feelings with masturbation;^{25,49} cultural and religious beliefs;^{41,45} poor success rate of the procedure for fertility preservation procedure;^{45,46} and young age at diagnosis^{40,52} are barriers

Malmö, Sweden (Prof A Giwercman PhD); Starship Blood and Cancer Centre, Starship Hospital, Auckland, New Zealand (S E Hunter PhD); Memorial Sloan Kettering Cancer Center, New York, NY, USA (J F Kelvin MSN); Department of Pediatrics, Emory University School of Medicine, Emory University, Atlanta, GA, USA (Prof J L Klosky PhD); Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA (Prof J L Klosky); Department of Obstetrics and Gynecology (Prof J S E Laven PhD) and Department of Pediatric Hematology and Oncology (Prof M M van den Heuvel-Eibrink), Sophia Children's Hospital and Pituitary Center Rotterdam, Endocrinology Section, Department of Medicine (S J C M M Neggers), Erasmus MC, Rotterdam, Netherlands; Division of Pediatric Surgery and Division of Hematology, Oncology, and Stem Cell Transplantation, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA (B A Lockart DNP); Department of Obstetrics and

Gynaecology, Royal Women's Hospital, University of Melbourne, Melbourne, VIC, Australia (M Peate PhD); Centre for Reviews and Dissemination, University of York, York, UK (B Phillips PhD); Adolescent Young Adult Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA (D R Reed MD); Division of Pediatric Hematology/Oncology, University Children's Hospital, Inselspital, Bern, Switzerland (E M E Tinner MD); Boyne Research Institute, Drogheda, Ireland (J Byrne PhD); Department of Medical Psychology, Radboudumc Nijmegen, Nijmegen, Netherlands (C M Verhaak PhD); Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia (A Anazodo PhD); Nelune Comprehensive Cancer Centre, Prince of Wales Hospital, Sydney, NSW, Australia (A Anazodo); School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia (A Anazodo); Division of Gynecology and Reproduction, Department of Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden (K Rodriguez-Wallberg PhD); Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden (K Rodriguez-Wallberg); Children and Young Peoples' Cancer Service, University College London Hospitals NHS Foundation Trust, London, UK (A Brownsdon BSc); Department of Paediatric Haematology and Oncology, Royal Hospital for Sick Children, Edinburgh, UK (Prof W H Wallace MD); Department of Paediatric and Adolescent Haematology/Oncology, Great North Children's Hospital, Newcastle upon Tyne, UK (R Skinner FRCPCH); Newcastle University Centre for Cancer, Newcastle upon Tyne, UK (R Skinner); Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy (R Haupt MD); Boston Children's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Harvard University, Boston,

Panel 1: Conclusions of evidence for fertility preservation for patients with CAYA cancer

What are facilitators of and barriers to the communication of treatment-related infertility risk and options for fertility preservation?

Involvement of health-care providers, patients with CAYA cancer, and their families

- Some parents of male patients diagnosed at younger than 18 years want to control whether physicians discuss sperm banking with their child (very low-quality evidence)²⁴
- No studies investigated the involvement of female patients and parents in the communication of fertility preservation
- Some male patients who were diagnosed with cancer at younger than 18 years considered medical support by doctors to be important and few male patients who were diagnosed with cancer at younger than 18 years considered nursing support to be important (very low-quality evidence)²⁵
- Most doctors indicated taking a leading role, whereas most nursing staff indicated taking a helping role in providing information about fertility preservation to patients and parents (very low-quality evidence)²⁶
- Most doctors and few nursing staff felt confident in providing up-to-date information about fertility preservation to patients and parents (very low-quality evidence)²⁶

Involvement of patients with CAYA cancer in the decision making

- Most adolescents and young male adults (mean age 17.2 years [3-0]) reported the decision to be a personal one and many reported being influenced by parents in the decision to sperm bank (very low-quality evidence)²⁷
- Decisions about fertility preservation are essentially made jointly between male patients with cancer and their parents (low-quality evidence)^{25,27}
- Most parents considered their adolescent child (ie, aged 12-18 years) to be capable of participating in the decision-making process, whereas few parents considered their children aged 7-12 years to be capable of participating in the discussion about fertility preservation (low-quality evidence)²⁵
- No studies investigated views of female patients on decision making about procedures for fertility preservation

Satisfaction with the use of decision tools, educational materials, and strategies in the communication of treatment-related infertility risk and fertility preservation

- Health-care providers reported that existing educational materials about fertility preservation are sometimes scarce and the existing materials need to be improved and adapted to the patient population (moderate-quality evidence)²⁸⁻³⁴
- Most parents of childhood patients (ie, aged 0-18 years) with cancer were satisfied with the design and content of a newly developed decision aid for fertility preservation (very low-quality evidence)³⁵
- Most health-care providers were satisfied with newly developed decision tools, educational materials, and strategies available for the patient and health-care provider (very low-quality evidence)^{26,35,36}

Effectiveness of decision tools, educational materials, and strategies in the communication of treatment-related infertility risk and fertility preservation

Effect of interventions for patients and families on parent and patient outcomes:

- Education materials (ie, information flyer) or decision aid for patients with CAYA cancer and families increased knowledge in both patients and parents (very low-quality evidence)^{35,37}
- Education materials (ie, information flyer) for patients with CAYA cancer and families increased patient and parents' empowerment (very low-quality evidence)³⁷
- A web-based decision aid for fertility preservation was not significantly associated with decision regret in parents of patients with childhood cancer (ie, aged 0-18 years; very low-quality evidence)³⁵

Effect of interventions for patients and families on oncofertility clinical practice:

- Education materials (ie, information flyer) for patients with CAYA cancer and families was not significantly associated with use of cryopreservation (very low-quality evidence)³⁸
- Education materials (ie, information flyer) for patients with CAYA cancer and families improved consultation practice for fertility preservation (very low-quality evidence)³⁷

Effect of interventions for health-care providers, patients, and parents on health-care outcomes:

- A toolkit for fertility preservation for health-care providers, including educational materials, checklist, referral forms, and handouts for patients, increased paediatric oncology clinician's confidence levels (very low-quality evidence)²⁶

Effect of interventions for health-care providers, patients, and parents on oncofertility clinical practice:

- A toolkit for fertility preservation for health-care providers, including educational materials, checklist, referral forms, and handouts for patients, increased the likelihood of paediatric oncology clinicians providing verbal and written information about fertility preservation; no significant effect of the toolkit for fertility preservation on the likelihood of clinicians being involved in discussions about fertility preservation (very low-quality evidence)²⁶
- A bundled intervention, including educational material for clinicians and patients and a referral pathway, increased documented risk of fertility discussion, documented referral to fertility specialist, and documented outcomes for fertility preservation of patients with adolescent and young adult cancer (ie, aged 14-25 years; very low-quality evidence)³⁹
- The implementation of an opt-out mechanism (where default results in an automatic consult order) increased the likelihood of completing consultation for fertility preservation among patients with CAYA cancer; no significant association between the intervention and attempts for fertility preservation after consultation in patients with CAYA cancer (very low-quality evidence)⁴⁰

(Continues on next page)

(Panel 1 continued from previous page)

- A clinical support system for decision making, including electronic clinical oncofertility pathways and handouts for patients, provided perceived benefit to oncofertility clinical practice as reported by clinicians involved in paediatric oncofertility care (very low-quality evidence)³⁶

Barriers to pursuing fertility preservation as reported by patients with CAYA cancer and their families

Patient-related barriers:

- Patient with poor emotional or physical status, or both (moderate-quality evidence)^{25,41-47}
- Absence of interest (moderate-quality evidence)^{44,45,48}
- Scarcity of experience with, taboo related to, and embarrassing feelings with masturbation (moderate-quality evidence)^{25,49}
- Absence of patient self-efficacy for banking (moderate-quality evidence)^{50,51*}
- Young age at diagnosis (moderate-quality evidence)^{40,52}
- Insufficient information (low-quality evidence)⁴³

Procedure-related barriers:

- Experimental nature of the procedure for fertility preservation with the associated risks or complications (moderate-quality evidence)^{25,42,45,46,48,53,54}
- Time constraints regarding delaying treatment (moderate-quality evidence)^{25,45-48,55}
- Costs (moderate-quality evidence)^{43,45,53}
- Poor success rate of the procedure for fertility preservation (moderate-quality evidence)^{45,46}

Parent-related barriers:

- Parents have a highly stressed emotional status (moderate-quality evidence)^{44,54,56}
- Absence of parental or medical team recommendation, or both (moderate-quality evidence)^{49,50}
- Cultural or religious beliefs (moderate-quality evidence)^{41,45}
- Sensitive nature of the conversation about fertility preservation (parent-reported barrier; low-quality evidence)²⁴
- Absence of parental self-efficacy (low-quality evidence)⁴⁹

Barriers related to health-care providers and institutions:

- Absence of specific consultation by fertility specialist (low-quality evidence)⁵⁷
- Difficulty in finding proper facilities (low-quality evidence)⁴⁵
- Adult treatment centre versus non-adult treatment centre (low-quality evidence)⁴⁷

Barriers to communicating treatment-related infertility risk and fertility preservation with patients with CAYA cancer as reported by health-care providers

Patient-related barriers:

- Patient's poor prognosis, poor health status, and risks (moderate-quality evidence)^{31,32,44,48,52,53,58-63}
- Patient's young age (moderate-quality evidence)^{31,52,58,63}
- Patient's potential disinterest (moderate-quality evidence)^{60,62}
- Patient already has children (moderate-quality evidence)^{59,60}
- Positive HIV status (moderate-quality evidence)^{31,32}

- Patient's cultural or religious beliefs (moderate-quality evidence)^{30,64}
- Patient's emotional state and the perceived additional stress with fertility topic (moderate-quality evidence)^{58,62}
- No current partner (low-quality evidence)⁵⁹
- Difficulty of establishing sense of trust with patient (low-quality evidence)³⁰
- Patient has few language skills (low-quality evidence)⁶²
- Patient's sexual orientation (low-quality evidence)³¹

Parent-related barriers:

- Parent has highly stressed emotional status (moderate-quality evidence)^{33,58}
- Real or perceived parental absence of interest or knowledge (moderate-quality evidence)^{63,64}
- Absence of parental consent (moderate-quality evidence)^{44,48}
- Families' socioeconomic status (low-quality evidence)³⁰

Barriers related to health-care providers and institutions:

- Scarcity of knowledge, training, and educational materials, or unfamiliarity with or low availability of relevant guidelines, or both (moderate-quality evidence)^{30,31,33,34,59,61-66}
- Scarcity of time and time pressure to start treatment (moderate-quality evidence)^{32,44,48,56,58-61,64,67}
- Little access or inadequate referral pathways with relevant facilities and specialists (moderate-quality evidence)^{30,33,58,64-68}
- Difficulties completing consent forms (low-quality evidence)⁶⁴
- A problem with the cooperative system with the paediatrics department (low-quality evidence)⁶⁵
- Cost of procedure and storage (moderate-quality evidence)^{30,31,33,44,52,53,59,62,65,68}
- Experimental nature of the procedure for fertility preservation with the associated risks and complications (moderate-quality evidence)^{52,53,59,61}
- Adoption system is popular, potentially discouraging discussion or promotion of fertility preservation (low-quality evidence)⁶⁵

What are ethical issues related to fertility preservation (ungraded)?

Ethical issues regarding informed consent

- Informed consent to procedures for fertility preservation in minors and young adults^{5,64,67,69-97}
- Safeguarding and protecting patients' best interests when making decisions about fertility preservation^{67,71,72,76,78,82-87,91-94,98-107}

Ethical issues regarding communication

- Communication between health-care providers and patients and their parents, caregivers, and partners^{5,52,67,70,71,73-78,81,84-86,89,92,93,96,98-100,105-113}

Ethical issues regarding potential risks of procedures for fertility preservation

- Harms versus benefits of procedures for fertility preservation^{5,54,67,69-73,75,76,79,80,83,85-87,89,90,92-94,96,97,100-103,105-112,114-116}

(Continues on next page)

MA, USA (L B Kenney MD);
Division of Pediatric
Hematology and Oncology,
Weill Cornell Medicine, Cornell
University, New York, NY, USA
(J Levine MD); Institute for the
History, Philosophy, and Ethics
of Medicine, Johannes
Gutenberg University Medical
Center Mainz, Mainz, Germany
(Prof N W Paul PhD,
J Inthorn PhD)

Correspondence to:
Dr Renée L Mulder, Princess
Máxima Center for Pediatric
Oncology, Utrecht 3584 CS,
Netherlands
r.l.mulder@
prinsesmaximacentrum.nl

See Online for appendix

(Panel 1 continued from previous page)

- Experimental nature of procedures for fertility preservation^{69,71,72,76,82–84,91,93,109,110,117}
 - Psychological issues surrounding decisions about procedures of fertility preservation^{70,72,74,79–83,87,93,97,106,107,109}
 - Ethical issues regarding storage of patients' material
 - Decisions on use and disposal of stored tissue for fertility preservation^{71,73,74,78–81,85,93,102,114–116,118}
 - Decisions on posthumous use of stored material for fertility preservation^{5,64,69,71–74,79–81,83–85,88–90,92,93,99–103,108–111,114,115}
- Ethical issues regarding access to procedures for fertility preservation*
- Offering access to procedures for fertility preservation considering patients' cultural or religious background^{91,106,108,112}
 - Restoring patients' reproductive autonomy with procedures for fertility preservation^{69–74,108,114,118}

- Differences in services for fertility preservation across countries^{70,79,80,93,95,103,111,113,115}
- Ethical issues regarding financial costs in procedures for fertility preservation
- Expenses linked to procedures for fertility preservation, potential complications, storage of cryopreserved material, post-treatment assisted reproductive technology, adoption, or surrogacy^{69,78–80,87,89,108,109,111,113,118}

Ethical issues regarding post-treatment adoption in survivors of cancer

- Discrimination during post-treatment adoption¹⁰⁶

CAYA=childhood, adolescent, and young adult. * Potential overlap in patients.

to discussing treatment effects on fertility and options for fertility preservation. Additionally, low-quality evidence exists that the sensitive nature of conversations about fertility preservation,²⁴ absence of parental self-efficacy,⁴⁹ absence of specific fertility specialist consultation,⁵⁷ difficulty in finding proper facilities,⁴⁵ and insufficient information⁴³ are also barriers for the communication of fertility preservation.

Similarly, health-care providers experience barriers to counselling about infertility risk and fertility preservation that are related to related to patients, parents, health-care providers and institutions, and procedures (low-quality to moderate-quality evidence).^{30–34,44,48,52,53,56,58–64,66–68} The most reported barriers by health-care providers were patients' poor cancer prognosis, unstable health status and low infertility risk,^{31,32,44,48,52,53,58,59–63} scarcity of knowledge and training, unfamiliarity with relevant guidelines,^{30,31,33,34,59,61–66} time pressure to start treatment,^{32,44,48,56,58–61,64,67} restricted access to or inadequate referral pathways with relevant facilities and specialists,^{30,33,58,64,66–68} and costs of the procedure and storage.^{30,31,33,44,52,53,59,62,65,68}

Recommendations

Existing studies describe some of the facilitators for and barriers to providing information or communicating about treatment-related infertility risk and fertility preservation in patients with CAYA cancer. Our recommendations are based on existing knowledge about potential facilitators and barriers and the consensus of the guideline panel (appendix pp 15–17). The panel formulated recommendations regarding provision of information and communication about treatment-related infertility risk and options for fertility preservation (panel 2; recommendations about patient risk groups that should receive information and counselling were formulated by the male and female fertility preservation guideline panels).

Generally, multiple studies indicated that health-care providers were uncomfortable discussing fertility

preservation because they did not have adequate training and relevant educational materials, and they had difficulty keeping up to date with the latest reproductive health science.^{30,31,33,34,59,61–66} As such, we strongly recommend that health-care providers become familiar with the latest evidence-based recommendations, institutional policies, and professional educational resources on infertility risk and procedures for fertility preservation and that they maintain their knowledge with relevant, up-to-date training as appropriate (low-quality to moderate-quality evidence). Interdisciplinary meetings and networks between paediatric oncologists or oncology nurses and reproductive medicine specialists (ie, gynaecologist, endocrinologist [including paediatric endocrinologist], urologist, andrologist, fertility physician, and specialised nurses) can overcome knowledge gaps and ensure high-quality patient care by continuous learning and teaching. The choice of who should be involved in the communication process depends on the provider's knowledge, patient's disease state, and local access to fertility specialists, rather than identifying a particular discipline to assume this role. Possibilities of whom should assume this role include the paediatric oncologist, endocrinologist (including paediatric endocrinologist), fertility specialist, specialised nurse, or another relevant health-care provider. The panel also recommend that it is of crucial importance that a system is in place to identify who is responsible for having the discussion.

On the basis of the evidence indicating the patients' scarcity of information or interest,^{43–45,48,49,53} a patient's prognosis^{25,31,32,41–48,52,53,58–63} and age,^{31,40,52,58,63} and the experimental nature of the fertility preservation procedures and associated risks,^{25,42,45,46,48,52–54,59,61} we strongly recommend that health-care providers deliver clear, comprehensive, and age-appropriate information, and that they provide up-to-date written or online educational resources, or both, to patients and their families in appropriate languages and health-literacy levels (very low-quality to

moderate-quality evidence). Additionally, we strongly recommend that health-care providers deliver the information in a professional, neutral, and empathetic manner (low-quality to moderate-quality evidence).

We strongly recommend that health-care providers actively involve patients or their families, or both (on the basis of expert opinions in the absence of evidence). Additionally, we strongly recommend that health-care providers have a private conversation with the patient and a separate conversation with families regarding treatment-related infertility risk and procedures for fertility preservation, taking into consideration a patient's age, developmental status, and the family's cultural and religious beliefs (low-quality to moderate-quality evidence). We also strongly recommend that health-care providers provide emotional support to patients and their families during counselling about treatment-related infertility risk and fertility preservation and offer prompt psychosocial specialist referrals (eg, social workers and psychologists) as appropriate. This support is especially important in view of the patient's and family's highly stressed emotional status (low-quality to moderate-quality evidence). In relation to time constraints regarding treatment delay, we strongly recommend that health-care providers initiate counselling as early as possible after a cancer diagnosis is established and when a change in disease status occurs that requires treatment intensification with gonadotoxic agents or methods (low-quality to moderate-quality evidence). The panel recognises the need to offer counselling on an ongoing basis during treatment and throughout survivorship because the patient's wishes can change (low-quality to moderate-quality evidence). Finally, to overcome barriers that are related to the scarcity of specific fertility specialist consultation, inadequate referral pathways for accessing relevant facilities and specialists, and health-care providers' perceived discomfort with the fertility topic and high workload, we strongly recommend that hospitals establish referral pathways for accessing fertility specialists or fertility specialist centres where appropriate (low-quality to moderate-quality evidence).

What are the ethical considerations related to fertility preservation?

From the systematic literature review, we identified evidence related to ethical considerations in fertility preservation with the following overarching themes: informed consent, communication between health-care providers and patients, caregivers, and partners, potential risks of procedures for fertility preservation, gamete storage, access to fertility preservation procedures, financial cost of procedures for fertility preservation and post-treatment assisted reproductive technology, and adoption or surrogacy in patients with cancer (appendix pp 53–64). On the basis of the evidence and expert opinions, we formulated GPSs (panel 3). Notably, all ethical deliberations should be considered within the context of the relevant national legal framework.

Panel 2: Recommendations regarding ongoing communication of treatment-related infertility risk and fertility preservation in patients with childhood, adolescent, and young adult cancer

General

Health-care providers should (strong recommendations; very low-quality to moderate-quality evidence):

- Be familiar with the latest evidence-based recommendations, institutional policies, and professional educational resources on infertility risk and procedures for fertility preservation
- Maintain education with training where appropriate

Provision of information about treatment-related infertility risk and fertility preservation

Health-care providers should (strong recommendations; very low-quality to moderate-quality evidence):

- Deliver clear, comprehensive, and age-appropriate information in a professional, neutral, and empathetic manner
- Provide up-to-date written or online educational resources to patients and their parents, caregivers, or partners in appropriate languages and health-literacy levels

Communicating treatment-related infertility risk and fertility preservation

Health-care providers should (strong recommendations; very low-quality to moderate-quality evidence):*

- Involve patients or their parents, caregivers, or partners, or both
- Offer a private conversation with the patient depending on age
- Offer a separate conversation with parents, caregivers, or partners after consent or assent of the patient
- Consider the patient's age, developmental status, and the family's cultural and religious beliefs
- Provide emotional support to patients and their parents, caregivers, or partners during counselling about treatment-related infertility risk and fertility preservation and prompt psychosocial specialist referrals (eg, social workers and psychologists) as appropriate
- Initiate counselling as early as possible after a cancer diagnosis and a treatment plan have been established, or when a change in disease status occurs that requires treatment intensification with gonadotoxic agents or methods
- Offer counselling on an ongoing basis during treatment and throughout survivorship because the infertility risk or patient's ideas might change

Hospitals should (strong recommendation; very low-quality to moderate-quality evidence):

- Establish referral pathways for accessing fertility specialists or fertility specialist centres where appropriate

*The panel recommend that a system should be in place to identify who is responsible for having the discussion, considering the provider's knowledge, patient's disease state, and local access to fertility specialists.

Fertility preservation aims to give patients future reproductive autonomy. However, because of the risks of cancer treatment to fertility, the potentially scarce availability of fertility preservation, and the personal and social effects of fertility decisions, conflicts can exist between respect for patient autonomy and other medical values.^{69–74,108,114,118} Health-care providers need to assist patients and their families in the decision-making process by fostering the patient's autonomy in the context of future parenthood decisions before decisions regarding procedures for fertility preservation can be made, while

Panel 3: Recommendations regarding ethical issues about treatment-related infertility risk and fertility preservation in patients with childhood, adolescent, and young adult cancer

Ethical issues related to fertility preservation: good practice statements

Health-care providers should:

- Foster the autonomy of the patient
- Assess the patient's emotional, psychological, and intellectual status as part of the informed consent process
- Ensure that decisions about fertility preservation are driven by the patient's best interest and not by own interest or interest of parents, caregivers, or partner
- Encourage patients to consider the risks and the medical, social, and ethical contingencies of procedures for fertility preservation and future use of frozen tissue
- Address the uncertainty of future technologies during counselling about infertility risk and procedures for fertility preservation
- Include societal and ethical values that are connected to social parenthood (ie, adoption) and the potential discrimination when applying for adoption in the discussions with the patient and parents, caregivers, or partners about adoption
- Include a two-stage consent process with patients or their families, caregivers, or partners, or both: at diagnosis when the decision about harvesting and storing tissue is made and after therapy at a developmentally appropriate age when the decision of whether and how to use the stored material is made
- Be aware of the importance to determine upfront with patients and their families, caregivers, or partners the access of researchers to their stored gametes
- Be aware of the importance to determine upfront with patients and their families, caregivers, or partners the disposal of gametes and preserved tissue in the event of the patient's death
- Be aware of possible conflicts of interest between the needs of patients, parents, and caregivers, the potential short-term and long-term financial costs that are involved in procedures and storage for fertility preservation, and post-treatment costs that are associated with pursuing family building

also encouraging them to consider their personal notions of parenthood (GPS; panel 3). It is also important that health-care providers establish whether patients are emotionally, psychologically, and mentally competent to consent or assent to fertility preservation options.^{5,70,75–80} Taking these factors into consideration, the guideline panel recommends that health-care providers assess a patient's emotional, psychological, and intellectual status as part of the process for informed consent (GPS; panel 3). National legal regulations for procedures for informed consent with minors need to be met.

Decision making about future fertility can be challenging for patients who have been newly diagnosed with cancer. Patients might have difficulty making life-changing decisions for the future, especially when having physical and psychological trauma. Additionally, patients might feel uncertain about their future desires and struggle with balancing the short-term and long-term advantages and disadvantages of fertility preservation. Patients often make decisions together with their families. Parents might be driven by their own interest and emotions, but they need to contemplate what the child might desire when they are an adult and what is in the interest of their child.⁹⁸ Hence, we recommend that

health-care providers ensure that decisions about fertility preservation are not driven by their own interest or interest of parents, caregivers, or partners but are made in the patients' best interest instead (GPS; panel 3).

The literature emphasised that a patient's decision to pursue fertility preservation can be influenced by projected advances in technology.⁸¹ This influence is especially important when offering procedures with little or unknown efficacy to prepubertal children. Similarly, fertility preservation measures should not create unrealistic or false expectations (ie, raising hope and not fulfilling expectations) as fertility preservation does not guarantee future reproductive potential.^{72,74,79–83,109} It is important to balance realistic expectations, including the likelihood of success of gamete thawing, gamete transplantation, and future livebirths, with costs that are associated with fertility preservation procedures and post-treatment assisted reproductive technology, surrogacy, or adoption, with allowing hope for successful family building in the future. To balance the risks and benefits that are associated with experimental procedures that are available for prepubertal children, interventions for fertility preservation should be done within a research setting with appropriate participant approval. Ethical reflection can be built into the care pathway for each individual by undertaking a case-by-case ethical analysis, if necessary.¹⁰⁹ Therefore, we recommend that health-care providers address the uncertainty of future technologies during patient counselling about infertility risk and procedures for fertility preservation.

The process for informed consent should be dynamic, ongoing, and adapted as new information becomes available.^{83–85} The document regarding informed consent should disclose the risks and potential benefits of procedures for fertility preservation.^{69,81,86} Additionally, it is important that the consent process is divided in two stages: at diagnosis when the decision about harvesting and storing tissue is made and after therapy at a developmentally appropriate age (which might vary depending on the patient) when the decision of whether and how to use the stored material is made.^{69,70,72,73,77,79,80,82,85,87–89} We recommend that health-care providers emphasise this fact, pointing out that the decision to preserve gametes or tissue does not obligate them to use this material in the future. This discussion can be held at a later date, such as at a developmentally appropriate age after therapy (GPS; panel 3).

Regarding posthumous use of stored gametes, evidence from this systematic review emphasises the need to consider two issues: disposal of gametes and preserved tissue in the event of a patient's death^{5,64,69,71–74,79,80,85,88–93,99,100–102,108–111,114,115} and potential disagreement among family members about gamete disposal in the event of a patient's death.^{72,92,103} Hence, we recommend that health-care providers should be aware of the need to discuss and obtain approval by patients and their families regarding the disposal of stored gametes in the event of a patient's

death and that such stored material can be donated for scientific research (GPS; panel 3). Of importance is the communication of local, national, and international regulations about researcher access to stored gametes. In terms of possible conflicts of interest between the needs of patients, the potential financial costs involved in procedures for fertility preservation and storage, and the long-term costs associated with pursuing family building necessitated by fertility preservation,⁷⁸ we recommend that health-care providers consider these issues and offer referrals for charity or other programmes that might help to offset costs, when available (GPS; panel 3).

Discussion

We present a systematic review of the evidence and recommendations regarding ongoing communication about, and ethical considerations related to, fertility preservation in patients with CAYA cancer. The evidence-driven recommendations were derived from the consensus of an international multidisciplinary group of experts following critical analysis of the scientific knowledge from the published literature by use of the GRADE methodology. This CPG harmonises efforts across Europe, Canada, Australia, New Zealand, and the USA as part of the PanCareLIFE Consortium and in collaboration with the IGHG.^{15,16} The global dissemination of this guideline aims to assist health-care providers to effectively communicate with patients with CAYA cancer and their families about potential infertility risk and procedures for fertility preservation while considering ethical issues. This CPG is one of the three CPGs that we have developed in this Series, with the other two Series papers focusing on fertility preservation options for male¹¹⁹ and female¹²⁰ patients with CAYA cancer.

The systematic literature review disclosed a paucity of data related to facilitators of and barriers to communication about fertility preservation that was limited to evidence of very low to moderate quality. Our strong recommendations were based on the clinical expertise of the guideline panel on how to communicate treatment-related infertility risk and options for fertility preservation to patients and their families. It is important that future studies focus on interventions to facilitate communication about fertility preservation between health-care providers and patients and their families and to overcome identified barriers.

There is a scarcity of knowledge about or unfamiliarity with relevant guidelines, creating barriers for communicating about fertility preservation as reported by health-care providers.^{30,31,33,34,59,61,63–66,103,121,122} These barriers are in line with the main findings from a systematic review focusing on children and young adults with cancer⁹ and also from literature reviews including adult patients with cancer who are of reproductive age.^{123,124} This deficit in knowledge is closely related to the institutional barriers reported by health-care providers that we also identified. These barriers include the difficulties for health-care providers in building

and maintaining a knowledge base and the scarcity of appropriate training about legal and consent frameworks.⁶⁴ Clinician training in communication skills is recommended in the adult population as part of the American Society of Clinical Oncology CPG to optimise patient–clinician communication¹²⁵ and has also been recommended as an area for training and development for health-care providers caring for adolescents and young adults with cancer.¹²⁶ Web-based training for communication skills that has improved nurses' knowledge about the fertility needs of adolescents and young adults with cancer is an example of encouraging results in this area.¹²⁷ To overcome barriers in communicating infertility risk and fertility preservation, interventions have been developed to promote and facilitate discussions between health-care providers and patients and families.^{26,35–40} Studies have shown that including fertility preservation discussions in the clinical care pathway (with all relevant documentation easily accessible, such as electronic flowcharts, instruction booklets, checklists, referral forms, and handouts for patients and families) increased discussion rates and the health-care providers' confidence in providing up-to-date knowledge to patients.^{26,36}

The current CPG recommends providing patients and their families with up-to-date written or online educational resources, or both, in appropriate languages. Findings from the systematic review have showed that health-care providers reported that educational materials about fertility preservation are sometimes scarce and existing materials need to be improved and adapted to the patient population with CAYA cancer.^{28–34} Additionally, patients reported a scarcity of information about fertility preservation.^{43,48} Educational materials that provide age-appropriate information and tools to facilitate shared decision making for patients with CAYA cancer and their families have been developed within the past 2 years.^{35,37,38,128} We encourage wider dissemination of culturally sensitive print and electronic (ie, web-based and app-based) educational materials in different languages. Digital information platforms can offer novel mechanisms to facilitate access to up-to-date information based on evidence-based guidelines. In an evolving field such as fertility preservation, educational patient resources will have to be updated as new data emerge.

This systematic review identified that both patients and health-care providers endorsed concerns regarding the delay in initiation of therapy as a barrier to communication about fertility preservation and procedures for fertility preservation. As published in CPGs for fertility preservation for young adults and adults with cancer, the guideline panel recommends that health-care providers should initiate discussions about fertility preservation as early as possible after a diagnosis and treatment plan have been established.¹⁴ The present CPG also specifies that health-care providers should readdress fertility preservation in the event of a change in disease status that requires treatment intensification with gonadotoxic

agents or methods and throughout survivorship to assure continued understanding about potential cancer-related and treatment-related effects on infertility risk, in agreement with the American Society of Clinical Oncology guideline in fertility preservation.⁶ Risk perceptions are discordant from laboratory-evaluated gonadal functioning. It was observed that most survivors overestimated their infertility risk when their fertility status seemed normal.¹²⁹ It is therefore essential to provide ongoing communication about fertility throughout survivorship. Fertility discussions are a standard component of survivorship care. The IGHG guidelines for male and female gonadotoxicity provide information that is pertinent to risk groups and surveillance measures of reproductive function.^{3,4} The guideline panel also recommends offering separate private conversations about treatment-related infertility risk and fertility preservation to the patient, especially with growing age and maturity of the patient, and their families. These conversations are especially important for adolescents and young adults, as they might feel more comfortable engaging in conversations in which their privacy is respected.¹³⁰

The systematic review showed that some health-care providers considered patients' cultural and religious background as barriers to initiating communication about infertility risk and procedures for fertility preservation.³³ The guideline panel recognises the importance of integrating families' cultural and religious beliefs during discussions about treatment-related infertility risk and fertility preservation, and the need to deliver information in a professional, neutral, and empathetic manner at all times. Similarly, the guideline panel considers that health-care providers need to be prepared to address religious preferences as part of a holistic approach to patient care during counselling for fertility preservation.¹³¹

The strengths of this CPG are the evidence-based approach used, the transparency given in deriving and rating the strength of the recommendations formed, and the wide geographical representation and multi-disciplinary expertise of the guideline panel. The ongoing interactive relationship between the academics and clinicians who appraise the evidence and those who formulate recommendations also increases the validity and trustworthiness of our process for guideline development. We involved patient representatives from different countries to ensure that patient values were considered in the guideline development process. Comprehensive periodic updates of the recommendations are planned as fertility preservation is a rapidly evolving field. Acknowledging that the recommendations offered will be subjected to consideration through national entities, policies, and legislation, they have been carefully formulated to facilitate implementation in different health-care settings. Finally, in accordance with patients' and their families' desire for genetically-related children, this CPG aims to facilitate access to

fertility preservation services by patients with CAYA cancer and their families.

Conclusion

We have developed a transparent, rigorous, and evidence-based CPG that provides guidance for ongoing communication of infertility risk and options for fertility preservation by health-care professionals to patients with CAYA cancer and their families, taking into account the associated ethical considerations of these interventions. Implementation of the present CPG can facilitate communication between patients and health-care providers and potentially fulfil patients' desire for biological offspring. Health-care professionals can tailor these recommendations to their patients' needs. With this CPG, we ultimately expect to increase future international collaborative research for patients with CAYA cancer and their families.

Contributors

AF-G, RLM, EAHL, MMH, JL, WJET, LCMK, LBK, and MDvdW contributed to the conception and design of the study. All authors contributed to the search strategy, data extractions, and interpretation of the data. All authors and collaborators contributed to the formulation of the recommendations. AF-G, RLM, LCMK and MMH drafted the manuscript; and EvD-dB, GPQ, JPG, EAHL, KCB, HMvS, CB, TD, UD, AG, CG, SEH, JFK, JLK, JSEL, BAL, SJCMMN, MP, BP, DRR, EMET, JB, MV, MvdB, CMV, AA, KR-W, MMvdH-E, AB, WHW, DMG, RS, RH, LBK, JL, MDvdW, WJET, NWP, JI, and collaborators (for full details of the collaborators see the appendix, p 2) critically revised the manuscript. All authors and collaborators approved the final version of this Series paper.

Declaration of interests

JFK was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. MP is supported by a University of Melbourne Medicine, Dentistry and Health Sciences Fellowship. JB received grants from the Boyne Research Institute. AG reports grants from the Swedish Cancer Society and Swedish Childhood Cancer Society, during the conduct of the study; and grants from Ferring Pharmaceuticals and personal fees from Besins Pharmaceuticals, Sandoz, and Finox, outside the submitted work. DRR reports personal fees from LOXO Pharmaceuticals, Shire Pharmaceuticals, Janssen, and Epizyme, outside the submitted work. HMvS received funding from Pfizer and Ferring, outside the submitted work. All other authors declare no competing interests.

Acknowledgments

This study has received funding from the EU's Seventh Framework Programme for Research, Technological Development and Demonstration (grant agreement number 602030). We thank Rosalind McDougall (Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia), Adam Glaser (University of Leeds, UK), Zoltan Antal (Memorial Sloan Kettering Cancer Center, New York, NY, USA), Teresa Woodruff (Northwestern University, Chicago, IL, USA), Anja Borgmann-Staudt (Charité Universitätsmedizin, Berlin, Germany), and Joyce Reinecke (Alliance for Fertility Preservation, Lafayette, CA, USA) for critically appraising the recommendations as external reviewers and Eline van der Meulen (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) and Jaap den Hartogh (Dutch Childhood Cancer Parent Organization/VOX, De Bilt, Netherlands) as patient advocates. We also thank the PanCareLIFE Consortium (appendix p 3). The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

References

- 1 Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCare-5—a population-based study. *Lancet Oncol* 2014; 15: 35–47.

- 2 Phillips SM, Padgett LS, Leisenring WM, et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. *Cancer Epidemiol Biomarkers Prev* 2015; **24**: 653–63.
- 3 Skinner R, Mulder RL, Kremer LC, et al. Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *Lancet Oncol* 2017; **18**: e75–90.
- 4 van Dorp W, Mulder RL, Kremer LCM, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *J Clin Oncol* 2016; **34**: 3440–50.
- 5 Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. *J Clin Oncol* 2010; **28**: 4831–41.
- 6 Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. *J Clin Oncol* 2018; **36**: 1994–2001.
- 7 AYA Cancer Fertility Preservation Guidance Working Group, Clinical Oncology Society of Australia. Fertility preservation for AYAs diagnosed with cancer: guidance for health professionals. Sydney: Cancer Council Australia; 2018.
- 8 National Institute for Health and Clinical Excellence. Fertility: assessment and treatment for people with fertility problems. London: National Institute for Health and Clinical Excellence; 2013.
- 9 Vindrola-Padros C, Dyer KE, Cyrus J, Lubker IM. Healthcare professionals' views on discussing fertility preservation with young cancer patients: a mixed method systematic review of the literature. *Psychooncology* 2017; **26**: 4–14.
- 10 Klosky JL, Simmons JL, Russell KM, et al. Fertility as a priority among at-risk adolescent males newly diagnosed with cancer and their parents. *Support Care Cancer* 2015; **23**: 333–41.
- 11 Stein DM, Victorson DE, Choy JT, et al. Fertility preservation preferences and perspectives among adult male survivors of pediatric cancer and their parents. *J Adolesc Young Adult Oncol* 2014; **3**: 75–82.
- 12 Nahata L, Caltabellotta NM, Yeager ND, et al. Fertility perspectives and priorities among male adolescents and young adults in cancer survivorship. *Pediatr Blood Cancer* 2018; **65**: e27019.
- 13 Langeveld NE, Grootenhuys MA, Voûte PA, de Haan RJ, van den Bos C. Quality of life, self-esteem and worries in young adult survivors of childhood cancer. *Psychooncology* 2004; **13**: 867–81.
- 14 Font-Gonzalez A, Mulder RL, Loeffen EAH, et al. Fertility preservation in children, adolescents, and young adults with cancer: quality of clinical practice guidelines and variations in recommendations. *Cancer* 2016; **122**: 2216–23.
- 15 Kremer LCM, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Pediatr Blood Cancer* 2013; **60**: 543–49.
- 16 Byrne J, Grabow D, Campbell H, et al. PanCareLIFE: the scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. *Eur J Cancer* 2018; **103**: 227–37.
- 17 Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011; **64**: 383–94.
- 18 Lewin S, Booth A, Glenton C, et al. Applying GRADE-CERQual to qualitative evidence synthesis findings: introduction to the series. *Implement Sci* 2018; **13** (suppl 1): 2.
- 19 Mertz M, Kahrass H, Streh D. Current state of ethics literature synthesis: a systematic review of reviews. *BMC Med* 2016; **14**: 152.
- 20 McDougall R. Systematic reviews in bioethics: types, challenges, and value. *J Med Philos* 2014; **39**: 89–97.
- 21 Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004; **328**: 1490.
- 22 Gibbons RJ, Smith S, Antman E. American College of Cardiology/American Heart Association clinical practice guidelines: part I: where do they come from? *Circulation* 2003; **107**: 2979–86.
- 23 Weiss MJ, Hornby L, Shemie SD, Appleby A, Rochweg B. GRADEing the un-GRADE-able: a description of challenges in applying GRADE methods to the ethical and implementation questions of pediatric organ donation guidelines. *J Clin Epidemiol* 2018; **103**: 134–37.
- 24 de Vries MC, Bresters D, Engberts DP, Wit JM, van Leeuwen E. Attitudes of physicians and parents towards discussing infertility risks and semen cryopreservation with male adolescents diagnosed with cancer. *Pediatr Blood Cancer* 2009; **53**: 386–91.
- 25 Wyns C, Collienne C, Shenfield F, et al. Fertility preservation in the male pediatric population: factors influencing the decision of parents and children. *Hum Reprod* 2015; **30**: 2022–30.
- 26 Kemertzis MA, Ranjithakumaran H, Hand M, et al. Fertility preservation toolkit: a clinician resource to assist clinical discussion and decision making in pediatric and adolescent oncology. *J Pediatr Hematol Oncol* 2018; **40**: e133–39.
- 27 Ginsberg JP, Ogle SK, Tuchman LK, et al. Sperm banking for adolescent and young adult cancer patients: sperm quality, patient, and parent perspectives. *Pediatr Blood Cancer* 2008; **50**: 594–98.
- 28 Murphy D, Kasha P, Quinn GP, Sawczyn KK, Termuhlen AM. Development of a Spanish language fertility educational brochure for pediatric oncology families. *J Pediatr Adolesc Gynecol* 2014; **27**: 202–09.
- 29 Murphy D, Sawczyn KK, Quinn GP. Using a patient-centered approach to develop a fertility preservation brochure for pediatric oncology patients: a pilot study. *J Pediatr Adolesc Gynecol* 2012; **25**: 114–21.
- 30 Quinn GP, Vadaparampil ST. Fertility preservation and adolescent/young adult cancer patients: physician communication challenges. *J Adolesc Health* 2009; **44**: 394–400.
- 31 Reebals JF, Brown R, Buckner EB. Nurse practice issues regarding sperm banking in adolescent male cancer patients. *J Pediatr Oncol Nurs* 2006; **23**: 182–88.
- 32 Vadaparampil ST, Clayton H, Quinn GP, King LM, Nieder M, Wilson C. Pediatric oncology nurses' attitudes related to discussing fertility preservation with pediatric cancer patients and their families. *J Pediatr Oncol Nurs* 2007; **24**: 255–63.
- 33 Vadaparampil S, Quinn G, King L, Wilson C, Nieder M. Barriers to fertility preservation among pediatric oncologists. *Patient Educ Couns* 2008; **72**: 402–10.
- 34 Fuchs A, Kashanian JA, Clayman ML, et al. Pediatric oncology providers' attitudes and practice patterns regarding fertility preservation in adolescent male cancer patients. *J Pediatr Hematol Oncol* 2016; **38**: 118–22.
- 35 Allingham C, Gillam L, McCarthy M, et al. Fertility preservation in children and adolescents with cancer: pilot of a decision aid for parents of children and adolescents with cancer. *JMIR Pediatr Parent* 2018; **1**: e10463.
- 36 Hand M, Kemertzis MA, Peate M, et al. A clinical decision support system to assist pediatric oncofertility: a short report. *J Adolesc Young Adult Oncol* 2018; **7**: 509–13.
- 37 Borgmann-Staudt A, Kunstreich M, Schilling R, et al. Fertility knowledge and associated empowerment following an educational intervention for adolescent cancer patients. *Psychooncology* 2019; **28**: 2218–25.
- 38 Balcerek M, Schilling R, Byrne J, et al. Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries. *Eur J Pediatr* 2020; **179**: 51–60.
- 39 Bradford NK, Walker R, Henney R, Inglis P, Chan RJ. Improvements in clinical practice for fertility preservation among young cancer patients: results from bundled interventions. *J Adolesc Young Adult Oncol* 2018; **7**: 37–45.
- 40 Saraf AJ, Stanek J, Audino A, et al. Examining predictors and outcomes of fertility consults among children, adolescents, and young adults with cancer. *Pediatr Blood Cancer* 2018; **65**: e27409.
- 41 Bashore L. Semen preservation in male adolescents and young adults with cancer: one institution's experience. *Clin J Oncol Nurs* 2007; **11**: 381–86.
- 42 Ginsberg JP, Li Y, Carlson CA, et al. Testicular tissue cryopreservation in prepubertal male children: an analysis of parental decision-making. *Pediatr Blood Cancer* 2014; **61**: 1673–78.
- 43 Benedict C, Thom B, N Friedman D, et al. Young adult female cancer survivors' unmet information needs and reproductive concerns contribute to decisional conflict regarding posttreatment fertility preservation. *Cancer* 2016; **122**: 2101–09.

- 44 Diesch T, Roivo A, von der Weid N, et al. Fertility preservation practices in pediatric and adolescent cancer patients undergoing HSCT in Europe: a population-based survey. *Bone Marrow Transplant* 2017; **52**: 1022–28.
- 45 Khalife D, Kutteh W, Tarhini H, Khalil A, Beyrouthy C, Ghazeeri G. Parental attitudes toward fertility preservation in female adolescent cancer patients in Lebanon. *J Pediatr Adolesc Gynecol* 2019; **32**: 525–29.
- 46 Jayasuriya S, Peate M, Allingham C, et al. Satisfaction, disappointment and regret surrounding fertility preservation decisions in the paediatric and adolescent cancer population. *J Assist Reprod Genet* 2019; **36**: 1805–22.
- 47 Skaczkowski G, White V, Thompson K, et al. Factors influencing the documentation of fertility-related discussions for adolescents and young adults with cancer. *Eur J Oncol Nurs* 2018; **34**: 42–48.
- 48 Köhler TS, Kondapalli LA, Shah A, Chan S, Woodruff TK, Brannigan RE. Results from the survey for preservation of adolescent reproduction (SPARE) study: gender disparity in delivery of fertility preservation message to adolescents with cancer. *J Assist Reprod Genet* 2011; **28**: 269–77.
- 49 Klosky JL, Flynn JS, Lehmann V, et al. Parental influences on sperm banking attempts among adolescent males newly diagnosed with cancer. *Fertil Steril* 2017; **108**: 1043–49.
- 50 Klosky JL, Lehmann V, Flynn JS, et al. Patient factors associated with sperm cryopreservation among at-risk adolescents newly diagnosed with cancer. *Cancer* 2018; **124**: 3567–75.
- 51 Klosky JL, Wang F, Russell KM, et al. Prevalence and predictors of sperm banking in adolescents newly diagnosed with cancer: examination of adolescent, parent, and provider factors influencing fertility preservation outcomes. *J Clin Oncol* 2017; **35**: 3830–36.
- 52 Anderson RA, Weddell A, Spoudeas HA, et al. Do doctors discuss fertility issues before they treat young patients with cancer? *Hum Reprod* 2008; **23**: 2246–51.
- 53 Gupta AA, Donen RM, Sung L, et al. Testicular biopsy for fertility preservation in prepubertal boys with cancer: identifying preferences for procedure and reactions to disclosure practices. *J Urol* 2016; **196**: 219–24.
- 54 Ginsberg JP, Carlson CA, Lin K, et al. An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety. *Hum Reprod* 2010; **25**: 37–41.
- 55 Burns KCBC, Boudreau C, Panepinto JA. Attitudes regarding fertility preservation in female adolescent cancer patients. *J Pediatr Hematol Oncol* 2006; **28**: 350–54.
- 56 Diesch T, von der Weid NX, Szinnai G, Schaedelin S, De Geyter C, Rovó A. Fertility preservation in pediatric and adolescent cancer patients in Switzerland: a qualitative cross-sectional survey. *Cancer Epidemiol* 2016; **44**: 141–46.
- 57 Klosky JL, Anderson LE, Russell KM, et al. Provider influences on sperm banking outcomes among adolescent males newly diagnosed with cancer. *J Adolesc Health* 2017; **60**: 277–83.
- 58 Armuand GM, Nilsson J, Rodriguez-Wallberg KA, et al. Physicians' self-reported practice behaviour regarding fertility-related discussions in paediatric oncology in Sweden. *Psychooncology* 2017; **26**: 1684–90.
- 59 Campbell JE, Assanasen C, Robinson RD, Knudtson JF. Fertility preservation counseling for pediatric and adolescent cancer patients. *J Adolesc Young Adult Oncol* 2016; **5**: 58–63.
- 60 Forman EJ, Anders CK, Behera MA. Pilot survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. *J Reprod Med* 2009; **54**: 203–07.
- 61 Overbeek A, van den Berg M, Louwé L, et al. Practice, attitude and knowledge of Dutch paediatric oncologists regarding female fertility. *Neth J Med* 2014; **72**: 264–70.
- 62 Quinn GP, Vadaparampil ST, King L, et al. Impact of physicians' personal discomfort and patient prognosis on discussion of fertility preservation with young cancer patients. *Patient Educ Couns* 2009; **77**: 338–43.
- 63 Panagiotopoulou N, van Delft FW, Hale JP, Stewart JA. Fertility preservation care for children and adolescents with cancer: an inquiry to quantify professionals' barriers. *J Adolesc Young Adult Oncol* 2017; **6**: 422–28.
- 64 Crawshaw M, Glaser A, Hale J, Sloper P. Professionals' views on the issues and challenges arising from providing a fertility preservation service through sperm banking to teenage males with cancer. *Hum Fertil (Camb)* 2004; **7**: 23–30.
- 65 Takae S, Lee JR, Mahajan N, et al. Fertility preservation for child and adolescent cancer patients in Asian countries. *Front Endocrinol (Lausanne)* 2019; **10**: 655.
- 66 Clayton H, Quinn GP, Lee JH, et al. Trends in clinical practice and nurses' attitudes about fertility preservation for pediatric patients with cancer. *Oncol Nurs Forum* 2008; **35**: 249–55.
- 67 Lee PA, Rogol A, Houk CP. Optimizing potential for fertility: fertility preservation considerations for the pediatric endocrinologist. *Endocrinol Metab Clin North Am* 2009; **38**: 761–75.
- 68 Goodwin T, Elizabeth Oosterhuis B, Kiernan M, Hudson MM, Dahl GV. Attitudes and practices of pediatric oncology providers regarding fertility issues. *Pediatr Blood Cancer* 2007; **48**: 80–85.
- 69 Patrizio P, Butts S, Caplan A. Ovarian tissue preservation and future fertility: emerging technologies and ethical considerations. *J Natl Cancer Inst Monogr* 2005; **2005**: 107–10.
- 70 Tschudin S, Urech C. Between threat and hope—fertility preservation in young cancer patients. *Praxis (Bern 1994)* 2013; **102**: 1171–76 (in German).
- 71 Ramstein JJ, Halpern J, Gadzinski AJ, Brannigan RE, Smith JF. Ethical, moral, and theological insights into advances in male pediatric and adolescent fertility preservation. *Andrology* 2017; **5**: 631–39.
- 72 Algarroba GN, Sanfilippo JS, Valli-Pulaski H. Female fertility preservation in the pediatric and adolescent cancer patient population. *Best Pract Res Clin Obstet Gynaecol* 2018; **48**: 147–57.
- 73 Klipstein S, Fallat ME, Savelli S. Fertility preservation for pediatric and adolescent patients with cancer: medical and ethical considerations. *Pediatrics* 2020; **145**: e20193994.
- 74 Moravek MB, Appiah LC, Anazodo A, et al. Development of a pediatric fertility preservation program: a report from the pediatric initiative network of the oncofertility consortium. *J Adolesc Health* 2019; **64**: 563–73.
- 75 Bellew EAGD, Green DL, Law EW, Rizzuto PJ, McGaughey RW, Gallicano GI. Ovaries on ice: freezing fertility in preadolescent female cancer patients. *Biopreserv Biobank* 2012; **10**: 485–92.
- 76 Cohen CB. Ethical issues regarding fertility preservation in adolescents and children. *Pediatr Blood Cancer* 2009; **53**: 249–53.
- 77 Patrizio P, Caplan AL. Fertility preservation: ethical considerations. In: Donnez J, Kim SS, eds. Principles and practice of fertility preservation. Cambridge: Cambridge University Press, 2011: 479–87.
- 78 Rodriguez SB, Campo-Engelstein L, Clayman ML, et al. Pathways toward the future: points to consider for oncofertility oversight. *J Cancer Surviv* 2013; **7**: 140–45.
- 79 Deepinder F, Agarwal A. Approach to fertility preservation in adult and pre-pubertal males. In: Seli E, Agarwal A, eds. Fertility preservation emerging technologies and clinical applications. New York: Springer, 2012: 353–64.
- 80 Patrizio P. Ethical discussions in approaching fertility preservation. In: Seli E, Agarwal A, eds. Fertility preservation emerging technologies and clinical applications. New York: Springer, 2012: 19–25.
- 81 Van Den Broecke R, Pennings G, Van Der Elst J, Liu J, Dhont M. Ovarian tissue cryopreservation: therapeutic prospects and ethical reflections. *Reprod Biomed Online* 2001; **3**: 179–84.
- 82 Multidisciplinary Working Group convened by the British Fertility Society. A strategy for fertility services for survivors of childhood cancer. *Hum Fertil (Camb)* 2003; **6**: A1–39.
- 83 Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? *Lancet Oncol* 2005; **6**: 209–18.
- 84 Martin JR, Patrizio P. Options for fertility preservation in pediatric populations undergoing cancer chemotherapy. *Pediatr Endocrinol Rev* 2009; **6** (suppl 2): 306–14.
- 85 Allan S, Gook D, Jayasinghe Y. The impact of the law in helping or hindering fertility preservation for children with cancer facing gonadotoxic therapies. *J Law Med* 2018; **26**: 322–33.
- 86 Nisker J, Baylis F, McLeod C. Choice in fertility preservation in girls and adolescent women with cancer. *Cancer* 2006; **107** (suppl): 1686–89.
- 87 Picton HM, Wyns C, Anderson RA, et al. A European perspective on testicular tissue cryopreservation for fertility preservation in prepubertal and adolescent boys. *Hum Reprod* 2015; **30**: 2463–75.
- 88 Wallace WHB, Thomson AB. Preservation of fertility in children treated for cancer. *Arch Dis Child* 2003; **88**: 493–96.

- 89 Lau GA, Schaeffer AJ. Current standing and future directions in pediatric oncofertility: a narrative review. *Transl Androl Urol* 2018; 7 (suppl 3): S276–82.
- 90 Chuai Y, Xu X, Wang A. Preservation of fertility in females treated for cancer. *Int J Biol Sci* 2012; 8: 1005–12.
- 91 Sugarman J, Rosoff PM. Ethical issues in gamete preservation for children undergoing treatment for cancer. *J Androl* 2001; 22: 732–37.
- 92 Affdal AO, Ravitsky V. Parents' posthumous use of daughter's ovarian tissue: ethical dimensions. *Bioethics* 2019; 33: 82–90.
- 93 Saraf AJ, Nahata L. Fertility counseling and preservation: considerations for the pediatric endocrinologist. *Transl Pediatr* 2017; 6: 313–22.
- 94 Brougham MFH, Wallace WHB. Subfertility in children and young people treated for solid and haematological malignancies. *Br J Haematol* 2005; 131: 143–55.
- 95 Pacey AA. Fertility issues in survivors from adolescent cancers. *Cancer Treat Rev* 2007; 33: 646–55.
- 96 Chilvers RA, Hossain A, Phelps JY. The ethical challenges of providing fertility care to patients with chronic illness or terminal disease. *Semin Reprod Med* 2010; 28: 303–14.
- 97 Kim SS. Fertility preservation in female cancer patients: current developments and future directions. *Fertil Steril* 2006; 85: 1–11.
- 98 Elster NR. Legal aspects of fertility preservation. In: Donnez J, Kim SS, eds. Principles and practice of fertility preservation. Cambridge: Cambridge University Press, 2011: 488–96.
- 99 Ayensu-Coker L, Essig E, Breech LL, Lindheim S. Ethical quandaries in gamete-embryo cryopreservation related to oncofertility. *J Law Med Ethics* 2013; 41: 711–19.
- 100 Janson PO. Possibilities of fertility preservation in children and young adults undergoing treatment for malignancy. *Acta Obstet Gynecol Scand* 2000; 79: 240–43.
- 101 Marsden DE, Hacker N. Fertility effects of cancer treatment. *Aust Fam Physician* 2003; 32: 9–13.
- 102 Zakak NN. Fertility issues of childhood cancer survivors: the role of the pediatric nurse practitioner in fertility preservation. *J Pediatr Oncol Nurs* 2009; 26: 48–59.
- 103 Resetkova N, Hayashi M, Kolp LA, Christianson MS. Fertility preservation for prepubertal girls: update and current challenges. *Curr Obstet Gynecol Rep* 2013; 2: 218–25.
- 104 Wallace WHB, Kelsey TW, Anderson RA. Fertility preservation in pre-pubertal girls with cancer: the role of ovarian tissue cryopreservation. *Fertil Steril* 2016; 105: 6–12.
- 105 Di Pietro ML, Teleman AA. Cryopreservation of testicular tissue in pediatrics: practical and ethical issues. *J Matern Fetal Neonatal Med* 2013; 26: 1524–27.
- 106 Schover LR. Patient attitudes toward fertility preservation. *Pediatr Blood Cancer* 2009; 53: 281–84.
- 107 Li N, Jayasinghe Y, Kemertzis MA, Moore P, Peate M. Fertility preservation in pediatric and adolescent oncology patients: the decision-making process of parents. *J Adolesc Young Adult Oncol* 2017; 6: 213–22.
- 108 Zoloth L, Backhus L, Woodruff T. Waiting to be born: the ethical implications of the generation of “NUBorn” and “NUAge” mice from pre-pubertal ovarian tissue. *Am J Bioeth* 2008; 8: 21–29.
- 109 McDougall RJ, Gillam L, Delany C, Jayasinghe Y. Ethics of fertility preservation for prepubertal children: should clinicians offer procedures where efficacy is largely unproven? *J Med Ethics* 2018; 44: 27–31.
- 110 Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. *J Clin Oncol* 2013; 31: 1239–47.
- 111 Sisk BA, Canavera K, Sharma A, Baker JN, Johnson LM. Ethical issues in the care of adolescent and young adult oncology patients. *Pediatr Blood Cancer* 2019; 66: e27608.
- 112 Hussein AA, Tran ND, Smith JF. Fertility preservation for boys and adolescents facing sterilizing medical therapy. *Transl Androl Urol* 2014; 3: 382–90.
- 113 Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: the global framework. *Cancer Treat Rev* 2014; 40: 1019–27.
- 114 Shah DK, Goldman E, Fisseha S. Medical, ethical, and legal considerations in fertility preservation. *Int J Gynaecol Obstet* 2011; 115: 11–15.
- 115 Levine JM, Kelvin JF, Quinn GP, Gracia CR. Infertility in reproductive-age female cancer survivors. *Cancer* 2015; 121: 1532–39.
- 116 Burton KA, Wallace WH, Critchley HO. Female reproductive potential post-treatment for childhood cancer. *Hosp Med* 2002; 63: 522–27.
- 117 Aslam I, Fishel S, Moore H, Dowell K, Thornton S. Fertility preservation of boys undergoing anti-cancer therapy: a review of the existing situation and prospects for the future. *Hum Reprod* 2000; 15: 2154–59.
- 118 Ruutinen T, Miller S, Caplan A, Ginsberg JP. Expanding access to testicular tissue cryopreservation: an analysis by analogy. *Am J Bioeth* 2013; 13: 28–35.
- 119 Mulder RL, Font-Gonzalez A, Green DM, et al. Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol* 2021; 22: e57–67.
- 120 Mulder RL, Font-Gonzalez A, Hudson MM, et al. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol* 2021; 22: e45–56.
- 121 Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists' attitudes and practices regarding banking sperm before cancer treatment. *J Clin Oncol* 2002; 20: 1890–97.
- 122 Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. *J Clin Oncol* 2002; 20: 1880–89.
- 123 Daly C, Micic S, Facey M, et al. A review of factors affecting patient fertility preservation discussions & decision-making from the perspectives of patients and providers. *Eur J Cancer Care (Engl)* 2019; 28: e12945.
- 124 Panagiotopoulou N, Ghuman N, Sandher R, Herbert M, Stewart JA. Barriers and facilitators towards fertility preservation care for cancer patients: a meta-synthesis. *Eur J Cancer Care (Engl)* 2018; 27: e12428.
- 125 Gilligan T, Coyle N, Frankel RM, et al. Patient-clinician communication: American Society of Clinical Oncology consensus guideline. *J Clin Oncol* 2017; 35: 3618–32.
- 126 Hayes-Lattin B, Mathews-Bradshaw B, Siegel S. Adolescent and young adult oncology training for health professionals: a position statement. *J Clin Oncol* 2010; 28: 4858–61.
- 127 Vadaparampil ST, Gwede CK, Meade C, et al. ENRICH: a promising oncology nurse training program to implement ASCO clinical practice guidelines on fertility for AYA cancer patients. *Patient Educ Couns* 2016; 99: 1907–10.
- 128 Rodriguez-Wallberg KA, Borgström B, Petersen C, et al. National guidelines and multilingual age-adapted patient brochures and videos as decision aids for fertility preservation (FP) of children and teenagers with cancer—a multidisciplinary effort to improve children's information and access to FP in Sweden. *Acta Obstet Gynecol Scand* 2019; 98: 679–80.
- 129 Lehmann V, Chemaillé W, Lu L, et al. Gonadal functioning and perceptions of infertility risk among adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. *J Clin Oncol* 2019; 37: 893–902.
- 130 Nahata L, Quinn GP, Tishelman AC. Counseling in pediatric populations at risk for infertility and/or sexual function concerns. *Pediatrics* 2018; 142: e20181435.
- 131 Hanselin MR, Roybal DL, Leininger TB. Ethics and oncofertility: a call for religious sensitivity. *J Oncol Pract* 2017; 13: e582–89.

© 2021 Elsevier Ltd. All rights reserved.